Apr 16, 2025, 09:28
Myeloma Paper of the Day, April 16th, suggested by Robert Orlowski
Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Study of outcomes in relapsed/refractory LPL/Waldenström txd with venetoclax -> ORR and MRR 70% and 63%; median and 2-year PFS 28.5 months and 57%; median and 2-year OS not reached and 82%; prior BTK inhibitor only factor associated with PFS.”
Authors: Y. Sawalha, S. Sarosiek, R. L. Welkie, S. Seif, S. Thapa, P. Kapoor, A. Grajales-Cruz, K. H. Shain, S. K. Thomas, J. J. Castillo et al.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 17:53
Apr 19, 2025, 17:17
Apr 19, 2025, 17:01
Apr 19, 2025, 16:44
Apr 19, 2025, 16:23